AlphaQuest LLC Has $34,000 Stake in Evolent Health, Inc. (NYSE:EVH)

AlphaQuest LLC raised its holdings in Evolent Health, Inc. (NYSE:EVH) by 21,650.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,045 shares of the technology company’s stock after buying an additional 3,031 shares during the period. AlphaQuest LLC’s holdings in Evolent Health were worth $34,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Edgestream Partners L.P. bought a new stake in shares of Evolent Health during the 4th quarter worth about $1,995,000. Prescott Group Capital Management L.L.C. acquired a new position in Evolent Health in the 4th quarter valued at approximately $1,713,000. Raymond James Financial Inc. acquired a new position in Evolent Health in the 4th quarter valued at approximately $2,542,000. WoodTrust Financial Corp boosted its stake in shares of Evolent Health by 28.7% in the 4th quarter. WoodTrust Financial Corp now owns 54,900 shares of the technology company’s stock valued at $618,000 after purchasing an additional 12,250 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Evolent Health by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 918,992 shares of the technology company’s stock valued at $10,339,000 after purchasing an additional 6,597 shares during the last quarter.

Evolent Health Stock Down 3.5 %

Shares of NYSE EVH opened at $9.61 on Friday. The firm has a fifty day simple moving average of $9.93 and a two-hundred day simple moving average of $16.26. The firm has a market capitalization of $1.12 billion, a PE ratio of -11.72 and a beta of 1.49. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 12 month low of $8.35 and a 12 month high of $33.63.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $646.54 million for the quarter, compared to analysts’ expectations of $650.92 million. Equities analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Insider Activity

In other Evolent Health news, Director Brendan B. Springstubb acquired 5,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the purchase, the director now directly owns 11,842 shares of the company’s stock, valued at approximately $103,617.50. This trade represents a 73.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Seth Blackley bought 55,225 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the purchase, the chief executive officer now owns 762,217 shares in the company, valued at $6,867,575.17. This trade represents a 7.81 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,000 shares of company stock valued at $666,315 in the last 90 days. 1.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on EVH. Truist Financial cut their target price on shares of Evolent Health from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. BTIG Research cut their target price on shares of Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. reduced their price objective on shares of Evolent Health from $13.00 to $12.00 and set an “overweight” rating for the company in a research note on Monday, March 10th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Evolent Health in a research note on Friday, February 21st. Finally, Royal Bank of Canada lowered their price objective on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Evolent Health has a consensus rating of “Buy” and an average target price of $17.71.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.